Pharmaceutical compositions comprising poh derivatives

Abstract

The present invention provides for a perillyl alcohol (POH) carbamate, such as POH-Rolipram. The present invention also provides for a method of treating a disease such as cancer, by delivering to a patient a therapeutically effective amount of POH-Rolipram.

What is claimed is: 
     
         1 . A composition comprising a perillyl alcohol carbamate, wherein the perillyl alcohol carbamate comprises perillyl alcohol conjugated with rolipram. 
     
     
         2 . The composition of  claim 1 , wherein the perillyl alcohol carbamate is 4-(3-cyclopentyloxy-4-methoxy phenyl)-2-oxo-pyrrolidine-1-carboxylic acid 4-isopropenyl cyclohex-1-enylmethyl ester. 
     
     
         3 . A method for treating a glioblastoma in a mammal, comprising delivering to the mammal a therapeutically effective amount of a perillyl alcohol carbamate, wherein the perillyl alcohol carbamate comprises perillyl alcohol conjugated with rolipram. 
     
     
         4 . The method of  claim 3 , further comprising treating the mammal with radiation. 
     
     
         5 . The method of  claim 3 , further comprising delivering to the mammal a chemotherapeutic agent. 
     
     
         6 . The method of  claim 3 , wherein the perillyl alcohol carbamate is administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly. 
     
     
         7 . The method of  claim 6 , wherein the perillyl alcohol carbamate is administered intranasally using an atomizer. 
     
     
         8 . The method of  claim 3 , wherein the perillyl alcohol carbamate is 4-(3-cyclopentyloxy-4-methoxy phenyl)-2-oxo-pyrrolidine-1-carboxylic acid 4-isopropenyl cyclohex-1-enylmethyl ester. 
     
     
         9 . A method for treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a perillyl alcohol carbamate using a nasal delivery device, wherein the perillyl alcohol carbamate comprises perillyl alcohol conjugated with rolipram. 
     
     
         10 . The method of  claim 9 , wherein the nasal delivery device is selected from the group consisting of an intranasal inhaler, an intranasal spray device, an atomizer, a nebulizer, a metered dose inhaler (MDI), a pressurized dose inhaler, an insufflator, a unit dose container, a pump, a dropper, a nasal spray bottle, a squeeze bottle and a bi-directional device. 
     
     
         11 . The method of  claim 9 , wherein the disease is cancer. 
     
     
         12 . The method of  claim 11 , wherein the cancer is a tumor of the nervous system. 
     
     
         13 . The method of  claim 12 , wherein the tumor is a glioblastoma. 
     
     
         14 . The method of  claim 9 , further comprising the step of treating the mammal with radiation. 
     
     
         15 . The method of  claim 9 , further comprising the step of delivering to the mammal a chemotherapeutic agent.